Literature DB >> 4039530

Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations.

D P Kelsen, N Alcock, C W Young.   

Abstract

Plasma platinum concentrations were measured in 45 patients receiving 46 courses of cisplatin (DDP) 100-120 mg/m2 and in 21 patients receiving 35-60 mg/m2. Samples were drawn 5 minutes, 24, and 48 hours following completion of the DDP infusion. Nephrotoxicity was defined as a greater than 50% increase in serum creatinine measured at 24 and/or 48 hours when compared to the baseline pretreatment value. In patients receiving DDP 100-120 mg/m2, 5/20 with 5-minute plasma platinum concentrations greater than 6 micrograms/ml developed nephrotoxicity; 0/26 with concentrations less than 6 micrograms/ml became nephrotoxic (p less than 0.05). Concentrations at 24 and 48 hours in toxic and nontoxic patients were similar. Five-minute plasma platinum concentrations in excess of 6 micrograms/ml did not occur in the 21 patients receiving DDP 35-60 mg/m2. Only one of these 21 patients became nephrotoxic. The data suggest that an increased incidence of acute nephrotoxicity is related to high peak plasma platinum concentrations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039530

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  12 in total

1.  Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.

Authors:  Tomoko Ogawa; Seiji Niho; Shunji Nagai; Takashi Kojima; Yoshiko Nishimura; Yuichiro Ohe; Naoki Kondo; Takuhiro Yamaguchi; Kazushi Endo; Keishiro Izumi; Hironobu Minami
Journal:  Int J Clin Oncol       Date:  2012-10-05       Impact factor: 3.402

3.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 5.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

6.  Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.

Authors:  W P Petros; S G Chaney; D C Smith; J Fangmeier; M Sakata; T D Brown; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 7.  Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.

Authors:  P Canal; E Gamelin; G Vassal; J Robert
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

8.  Correlations between cis-platinum dosage and toxicity in a guinea pig model.

Authors:  L J Hoeve; I R Mertens zur Borg; M Rodenburg; M P Brocaar; B G Groen
Journal:  Arch Otorhinolaryngol       Date:  1988

9.  A kidney injury molecule-1 (Kim-1) gene reporter in a mouse artificial chromosome: the responsiveness to cisplatin toxicity in immortalized mouse kidney S3 cells.

Authors:  Kenji Kokura; Yasushi Kuromi; Takeshi Endo; Naohiko Anzai; Yasuhiro Kazuki; Mitsuo Oshimura; Tetsuya Ohbayashi
Journal:  J Gene Med       Date:  2016-10       Impact factor: 4.565

10.  EPIC: an effective low toxicity regimen for relapsing lymphoma.

Authors:  T Hickish; A Roldan; D Cunningham; J Mansi; S Ashley; V Nicolson; M E Gore; D Catovsky; I E Smith
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.